Sangamo Therapeutics, Inc. (SGMO)
收市後：
- Zacks
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Insider Monkey
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised […]
- InvestorPlace
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test effective treatments. With so much less known about rare diseases than common ones, scientists may find themselves groping blindly trying to develop drugs and treatments. Rare diseases have less financial incentive as well. Fewer people having a disease means fewer patients that a treatment can be sold to. Th
